RESEARCH DATABASE

InBody Scholar

InBody continues to work closely with academic researchers on a global scale to develop more in-depth clinical applications of body composition.
With our long history in the industry, we provide more than 6,000 research and publications.
Research title with ★ indicates InBody recommended paper.

Effects of dapagliflozin on body composition and liver tests in patients with nonalcoholic steatohepatitis associated with type

Hepatology
Author
Hiroshi Tobita et al.
Used Parameters : TBW, FFM, SLM, SMM, SMI, BFM, PBF, Protein
Publication Year : 2017
Country : Japan
Journal : Current Therapeutic Research
Background Nonalcoholic steatohepatitis (NASH) is an active form of nonalcoholic fatty liver disease. Risk factors for NASH include type 2 diabetes mellitus (T2DM) and obesity. Sodium–glucose cotransporter 2 (SGLT2) inhibitors used to treat T2DM prevent glucose reabsorption in the kidney and increase glucose urinary excretion. Dapagliflozin is a potent, selective SGLT2 inhibitor that reduces hyperglycemia in patients with T2DM and has been demonstrated to reduce some complications associated with NASH in rodent models …
Full text
List
Powered by KBoard